166 related articles for article (PubMed ID: 36682142)
1. Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer.
Scherpereel A; Martin E; Brouchet L; Corre R; Duruisseaux M; Falcoz PE; Giraud P; Le Péchoux C; Wislez M; Alifano M
Lung Cancer; 2023 Mar; 177():21-28. PubMed ID: 36682142
[TBL] [Abstract][Full Text] [Related]
2. Role of surgery in N2 NSCLC: pros.
Shien K; Toyooka S
Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
[TBL] [Abstract][Full Text] [Related]
3. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.
Veeramachaneni NK; Feins RH; Stephenson BJ; Edwards LJ; Fernandez FG
Ann Thorac Surg; 2012 Sep; 94(3):922-6; discussion 926-8. PubMed ID: 22742842
[TBL] [Abstract][Full Text] [Related]
4. Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board.
Mainguene J; Basse C; Girard P; Beaucaire-Danel S; Cao K; Brian E; Grigoroiu M; Gossot D; Luporsi M; Perrot L; Vieira T; Caliandro R; Daniel C; Seguin-Givelet A; Girard N
Lung Cancer; 2022 Jan; 163():51-58. PubMed ID: 34922144
[TBL] [Abstract][Full Text] [Related]
5. Current status of induction treatment for N2-Stage III non-small cell lung cancer.
Yamaguchi M; Sugio K
Gen Thorac Cardiovasc Surg; 2014 Nov; 62(11):651-9. PubMed ID: 25355643
[TBL] [Abstract][Full Text] [Related]
6. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
7. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
[TBL] [Abstract][Full Text] [Related]
8. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection.
Tanner NT; Gomez M; Rainwater C; Nietert PJ; Simon GR; Green MR; Silvestri GA
J Thorac Oncol; 2012 Feb; 7(2):365-9. PubMed ID: 22237260
[TBL] [Abstract][Full Text] [Related]
9. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
10. [Clinical analysis of skip N2 metastases in stage IIIA non-small cell lung cancer].
Liu K; Chen HL; You QS; Huang JF; Wang H
Ai Zheng; 2009 Jul; 28(7):725-9. PubMed ID: 19624899
[TBL] [Abstract][Full Text] [Related]
11. Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).
Ma Q; Liu D; Guo Y; Shi B; Song Z; Tian Y
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):342-8. PubMed ID: 20677562
[TBL] [Abstract][Full Text] [Related]
12. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
Isla D; Felip E; Garrido P; Insa A; Majem M; Remon J; Trigo JM; de Castro J
Clin Transl Oncol; 2023 Jan; 25(1):283-291. PubMed ID: 36168085
[TBL] [Abstract][Full Text] [Related]
13. Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment.
Stamatis G; Müller S; Weinreich G; Schwarz B; Eberhardt W; Pöttgen C; Aigner C
Eur J Cardiothorac Surg; 2022 Jan; 61(2):269-276. PubMed ID: 34368849
[TBL] [Abstract][Full Text] [Related]
14. N2 disease in non-small-cell lung cancer: straight to surgery?
Sanchez-Lorente D; Guzman R; Boada M; Guirao A; Carriel N; Molins L
Future Oncol; 2018 Mar; 14(6s):13-16. PubMed ID: 29664353
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
Giannitto GC; Giuffrida D; Pappalardo A; Russo A; Vincenzi B; Saita S; Potenza E; Marletta F; La Venia G; Castorina S; Bordonaro R
Oncology; 2005; 69(4):295-300. PubMed ID: 16282709
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).
Elias AD; Skarin AT; Leong T; Mentzer S; Strauss G; Lynch T; Shulman L; Jacobs C; Abner A; Baldini EH; Frei E; Sugarbaker DJ
Lung Cancer; 1997 May; 17(1):147-61. PubMed ID: 9194034
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
[TBL] [Abstract][Full Text] [Related]
18. Extended surgical resection in stage III non-small cell lung cancer.
Hillinger S; Weder W
Front Radiat Ther Oncol; 2010; 42():115-121. PubMed ID: 19955797
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival after complete mediastinal lymph node resection and lobectomy in patients with bulky N2 non-small cell lung cancer.
Sakuraba M; Takahashi N; Oh S; Miyasaka Y; Inagaki T; Suzuki K
Ann Thorac Cardiovasc Surg; 2011; 17(2):124-9. PubMed ID: 21597408
[TBL] [Abstract][Full Text] [Related]
20. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
